Abstract：
BACKGROUND: Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population.
METHODS: ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed.
RESULTS: Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51-96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.
CONCLUSIONS: In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.
METHODS: ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed.
RESULTS: Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51-96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.
CONCLUSIONS: In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.
摘要：
背景：嗅神经母细胞瘤（ONB）硬脑膜复发的治疗方法尚未标准化。我们评估了该人群中立体定向放射治疗（SBRT）的结果。
方法：纳入2013年至2022年期间接受前瞻性登记治疗的硬脑膜复发的ONB患者。肿瘤控制,生存,并对患者报告的生活质量进行分析.
结果：评估了14例32个硬脑膜病变的患者。硬膜复发时间为58.3个月。用SBRT治疗30个病变（94％），分三个部分，中位剂量为27Gy。两名患者（32个病灶中的3个；9%）出现了场内放射学进展，5例患者(38%)在非连续硬脑膜出现进展.两年局部控制为85％（95％CI：51-96％）。没有>3级急性毒性和1例晚期3级脑放射性坏死。
结论：在这项迄今为止最大的SBRT再放疗治疗ONB硬膜复发的研究中，可以达到高的局部控制率和最小的毒性。
方法：纳入2013年至2022年期间接受前瞻性登记治疗的硬脑膜复发的ONB患者。肿瘤控制,生存,并对患者报告的生活质量进行分析.
结果：评估了14例32个硬脑膜病变的患者。硬膜复发时间为58.3个月。用SBRT治疗30个病变（94％），分三个部分，中位剂量为27Gy。两名患者（32个病灶中的3个；9%）出现了场内放射学进展，5例患者(38%)在非连续硬脑膜出现进展.两年局部控制为85％（95％CI：51-96％）。没有>3级急性毒性和1例晚期3级脑放射性坏死。
结论：在这项迄今为止最大的SBRT再放疗治疗ONB硬膜复发的研究中，可以达到高的局部控制率和最小的毒性。
